RetinaCME
SLIDES-AUDIO LECTURECME

Navigating Evolving Protocols in the Treatment of Age-related Macular Degeneration

Author(s)/Faculty: W. Lloyd Clark, MD; Carl D. Regillo, MD, FACS; Rishi P. Singh, MD; Nathan C. Steinle, MD
Release Date: 12/30/2019Expiration Date: 12/29/2020
Credit Type: CMENumber of Credits: 1
Content Type: LectureProvider:
Intravitreal therapy has rapidly evolved to become a mainstay of treatment for many retinal diseases, offering patients delayed or arrested disease progression, with the possibility of regaining lost vision. The treatment of patients with neovascular age-related macular degeneration (nAMD) has been revolutionized by intravitreal anti-vascular endothelial growth factor (VEGF) therapy. However, long-term extensions of major clinical trials have not demonstrated great success in maintaining the dramatic vision gains obtained initially, particularly when as-needed dosing was used. Fixed-interval or treat-and-extend protocols, which generally use more frequent injections, have had greater success in maintaining vision gains. Further, newer protocols that allow for longer intervals between treatments are now available and hold promise in lessening treatment burden. In this educational activity, expert faculty discuss the latest evidence-based medicine regarding anti-VEGF protocols in the treatment of patients with nAMD.